Immunotherapy Poised to Move Forward Into Stage III NSCLC – OncLive
OncLiveImmunotherapy Poised to Move Forward Into Stage III NSCLCOncLiveIn September 2017, at the annual European Society for Medical Oncology (ESMO) Congress, researchers presented positive data from a phase III trial of durvalumab (Imfinzi) in patient… Continue reading
